Please login to the form below

Not currently logged in
Email:
Password:

Gilotrif

This page shows the latest Gilotrif news and features for those working in and with pharma, biotech and healthcare.

EMA starts firming up its stance on personalised medicines

EMA starts firming up its stance on personalised medicines

As more treatments like Pfizer’s Xalkori, Vertex’s Kalydeco and Boehringer Ingelheim’s Giotrif/Gilotrif come to market it also wants to better define those patients that will benefit from

Latest news

  • Boehringer stops Gilotrif head and neck cancer trials Boehringer stops Gilotrif head and neck cancer trials

    Boehringer stops Gilotrif head and neck cancer trials. Trial data suggests the drug is “ highly unlikely” to prolong patients’ remission. ... Boehringer Ingelheim has said it will abandon two trials of Gilotrif in head and neck cancer after

  • FDA approves expanded indication for Gilotrif FDA approves expanded indication for Gilotrif

    FDA approves expanded indication for Gilotrif. US body gives Boehringer Ingelheim’ s oral lung cancer treatment the nod. ... It showed Gilotrif achieved its primary objective of significantly improving progression-free survival when compared against

  • Boehringer launches iPhone app for patients on Gilotrif Boehringer launches iPhone app for patients on Gilotrif

    Boehringer launches iPhone app for patients on Gilotrif. App offers treatment guide for those taking its cancer drug. ... Boehringer Ingelheim has released an iPhone app for patients prescribed its cancer drug Gilotrif (afatinib).

  • Opdivo gains new US lung cancer licence Opdivo gains new US lung cancer licence

    Current marketed therapies for NSCLC includes AstraZeneca's Iressa (gefitinib), Roche's Avastin (bevacizumab), as well as more recent treatments such as Pfizer's Xalkori (crizotinib) and Boehringer's Gilotrif (afatinib).

  • Boehringer’s Vargatef approved in the EU for lung cancer Boehringer’s Vargatef approved in the EU for lung cancer

    cancer.”. The launch of Giotrif/Gilotrif in 2013 as a treatment lung cancer patients who express epidermal growth factor receptor (EGFR) marked Boehringer's entry onto the oncology market.

More from news
Approximately 6 fully matching, plus 13 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics